阿尔茨海默氏病的异质性通过神经心理测试概况鉴定确定
Truc Tran Thanh Nguyen1,2, Hsun-Hua Lee3,4,5,6, Li-Kai Huang4,7
1Graduate Institute of Biomedical Informatics, Division of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
PloS one
|October 5, 2023
概括
这项研究确定了阿尔茨海默病 (AD) 患者的两个不同的认知子组:一个具有记忆缺陷,另一个具有非记忆认知障碍. 这些发现突显了AD异质性,并可以为个性化治疗策略提供信息.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 认知科学 认知科学
背景情况:
- 阿尔茨海默病 (AD) 呈现出显著的异质性,使个性化治疗开发和临床试验招聘复杂化.
- 了解AD的认知变化对于推进治疗策略和改善患者分层至关重要.
研究的目的:
- 使用数据驱动方法,在可能患有阿尔茨海默病的患者队伍中识别不同的认知子组.
- 描述已识别的子组的认知概况和基线疾病严重程度.
- 在3年的随访期内检查这些子组的纵向疾病轨迹.
主要方法:
- 在认知能力查仪器的神经心理测试数据上采用非负矩阵因子化,一种聚类技术.
- 分析了台湾112名可能患有轻度至中度AD的个体的数据.
- 利用线性混合效应模型来评估3年内的疾病进展.
主要成果:
- 确定了两个主要的认知集群:一个记忆占主导地位的认知缺陷组 (62.5%) 和一个非记忆认知缺陷组 (37.5%).
- 记忆组在短期记忆和定向方面表现较差,但与非记忆组相比,注意力更好.
- 在基线时,记忆组呈现出更糟糕的全球认知状态和更高的痴呆症严重程度.
- 在两组群体之间在3年内没有观察到疾病发展轨迹的显著差异.
结论:
- 这项研究揭示了亚洲人口中可能出现阿尔茨海默氏症的认知异质性.
- 已识别的记忆和非记忆认知子组为AD变异性提供了见解.
- 这些发现可能有助于改进临床试验的参与者选择,并开发有针对性的治疗干预措施.
更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.9K
相关概念视频
Alzheimer's Disease: Overview
506
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
506
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
